Management of psoriatic arthritis

Psoriatic and Reactive Arthritis: A Companion to Rheumatology

Volumn , Issue , 2007, Pages 97-113

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882520293     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03622-1.50017-3     Document Type: Chapter

References (174)

1. Rahman P, Nguyen E, Cheung C, et al. Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol 2001, 28:1041-1044.
2. Husted JA, Gladman DD, Farewell VT, Cook RJ Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis Care Res 2001, 45:151-158.
3. Kirwan JR The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis & Rheumatism Council Low Dose Glucocorticoid study group. New Engl J Med 1995, 333:142-146.
4. Maksymowych W, Inman R, Stone M, et al. The Spondyloarthritis Research Consortium of Canada (SPARCC) Canadian Rheumatology Association Consensus on the Use of Anti-Tumor Necrosis Factor α-Directed Therapies in the Treatment of Spondyloarthritis. J Rheumatol 2003, 30:1356-1363.
5. Hilliquin P, Gregoir C, Menkes CJ [Value of pulse methylpred-nisolone in polyarticular forms of psoriatic rheumatism]. Rev Rhum Mal Osteoartic 1992, 59:160-161. In French.
6. Baker H, Ryan TJ Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol 1968, 80:771-793.
7. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A Department of Veterans Affairs cooperative study. Arthritis Rheum 1999, 42:2325-2329.
8. Farr M, Kitas GD, Waterhouse L, et al. Sulphasalazine in psoriatic arthritis: A double-blind placebo-controlled study. Br J Rheumatol 1990, 29:46.
9. Seideman P. Sulphasalazine treatment of psoriatic arthritis. Rheumatology 1990, 29:491-492.
10. Gupta AK, Grober JS, Hamilton TA, et al. Sulfasalazine therapy for psoriatic arthritis: A double-blind, placebo-controlled trial. J Rheumatol 1995, 22:894-898.
11. Fraser SM, Hopkins R, Hunter JA, et al. Sulphasalazine in the management of psoriatic arthritis. J Rheumatol 1993, 32:923-925.
12. Dougados M, van der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondyloarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995, 38:618-627.
13. Combe B, Goupille P, Kuntz JL, et al. Sulphasalazine in psoriatic arthritis: A randomised, multicentre, placebo-controlled study. J Rheumatol 1996, 35:664-668.
14. Rahman P, Gladman DD, Cook RJ, et al. The use of sulfasalazine in psoriatic arthritis: a clinical experience. J Rheumatol 1998, 25:1957-1961.
15. Black RL, O'Brien WM, Van Scott EJ, et al. Methotrexate therapy in psoriatic arthritis. JAMA 1964, 189:141.
16. Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo-controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984, 27:376.
17. Abu-Shakra M, Gladman DD, Thorne JC, et al. Long-term methotrexate therapy in psoriatic arthritis: Clinical and radio-logical outcome. J Rheumatol 1995, 22:241-245.
18. Wollina U, Stander K, Barta U. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis-short-and long-term toxicity in 104 patients. Clin Rheumatol. 2001, 20:406-410.
19. Pioro M, Cash J. Treatment of refractory psoriatic arthritis. Rheumatic Disease Clinics of North Am 1995, 21:129-148.
20. Mease P, Gladman D, Keystone E. Alefecept in combination with methotrexate for the treatment of psoriatic arthritis. Arthritis Rheum 2006, 54:1638-1645.
21. Carette S, Calin A, McCafferty JP, et al. A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis. Arthritis Rheum 1989, 32:158.
22. Dorwart BB, Gall EP, Schumacher HR, et al. Chrysotherapy in psoriatic arthritis. Arthritis Rheum 1978, 21:513.
23. Palit J, Hill J, Capell HA, et al. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol 1990, 29:280.
24. Espinoza LR, Zakraqui L, Espinoza CG, et al. Psoriatic arthritis: Clinical response and side effects to methotrexate therapy. J Rheumatol 1992, 19:872.
25. Dorwart BB, Gall EP, Schumacher HR, Krauser RE Chrysotherapy in psoriatic arthritis. Efficacy and toxicity compared to rheumatoid arthritis. Arthritis Rheum 1978, 21:513-515.
26. Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999, 93:198-208.
27. Manguso F, Oriente A, Peluso R, Oriente P. Leflunomide in psoriatic polyarthritis: an Italian pilot study. Arthritis Rheum 2001, 44(9S):S92.
28. Liang GC, Barr WG Long-term follow-up of the use of lefluno-mide in recalcitrant psoriatic arthritis and psoriasis. Arthritis Rheum 2001, 44(9S):S121.
29. Kaltwasser J, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum 2004, 50:1939-1950.
30. Baum J, Hurd E, Lewis D, et al. Treatment of psoriatic arthritis with 6-mercaptopurine. Arthritis Rheum 1973, 16:139.
31. Levy J, Paulus HE, Barnett EV, et al. A double-blind controlled evaluation of azathioprine treatment in rheumatoid arthritis and psoriatic arthritis. Arthritis Rheum 1972, 15:116.
32. Olivieri I, Salvarani C, Cantini F, et al. Therapy with cyclosporine in psoriatic arthritis. Semin Arthritis Rheum 1997, 27:36-43.
33. Fraser A, van Kuijk A, Westhovens R, et al. A randomised double-blind placebo-controlled multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005, 64:859-864.
34. Spadaro A, Riccieri V, Sili-Scavalli A, et al. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: A one-year prospective study. Clin Exp Rheumatol 1995, 13:589-593.
35. Kammer G, Sotar N, Gibson D, Schur P. Psoriatic arthritis: A clinical immunologic and HLA study of 100 patients. Semin Arthritis Rheum 1979, 9:75-95.
36. Gladman DD, Blake R, Brubacher B, et al. Chloroquine therapy in psoriatic arthritis. J Rheumatol 1992, 19:1724-1726.
37. Price R, Gibson T. D-penicillamine and psoriatic arthritis. Br J Rheumatol 1986, 25:228.
38. Seideman P, Fjellner B, Johannesson A. Psoriatic arthritis treated with oral colchicine. J Rheumatol 1987, 14:777.
39. Wahba A, Cohen H. Therapeutic trials with oral colchicine in psoriasis. Acta Derm Venereol (Stockh) 1980, 60:515.
40. Klinkhoff AV, Gertner E, Chalmers A, et al. Pilot study of etretinate in psoriatic arthritis. J Rheumatol 1989, 16:789.
41. Goupille P, Soutif D, Valat J. Treatment of psoriatic arthropathy. Semin Arthritis Rheum 1992, 21:109.
42. Wilfert J, Honigsmann H, Steiner G. Treatment of psoriatic arthritis by extracorporeal photochemotherapy. Br J Dermatol 1990, 122:225.
43. Matucci-Cerinic M, Lotti T, Cappugi P, et al. Somatostatin treatment of psoriatic arthritis. Int J Dermatol 1988, 27:56.
44. Fierlbeck G, Rassner G. Treatment of psoriasis and psoriatic arthritis with interferon gamma. J Invest Dermatol 1990, 95:138S.
45. O'Connell PG, Gerber LH, Digiovanna JJ, et al. Arthritis in patients with psoriasis treated with gamma-interferon. J Rheumatol 1992, 19:80.
46. Huckins D, Felson DT, Holick M. Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: A pilot study. Arthritis Rheum 1990, 33:1723.
47. Vahlquist C, Larsson M, Ernerudh J, et al. Treatment of psoriatic arthritis with extracorporeal photochemotherapy and conventional psoralen-ultraviolet A irradiation. Arthritis Rheum 1996, 39:1519-1523.
48. Peeters AJ, Dijkmans BA, van der Schroeff JG Fumaric acid therapy for psoriatic arthritis. A randomized, double-blind, placebo-controlled study. Br J Rheumatol 1992, 31:502-504.
49. Dalbeth N, Yeoman S, Dockerty J, et al. A randomized placebo-controlled trial of delipidated deglycolipidated Mycobacterium vacae as immunotherapy for psoriatic arhritis. Ann Rheum Dis 2004, 63:718-722.
50. Mease P, Antoni C. Psoriatic arthritis treatment: Biological response modifiers. Ann Rheum Dis 2005, 64(2):1178-1182.
51. Mease PJ Psoriatic arthritis therapy advances. Curr Opin Rheumatol 2005, 17:426-432.
52. Dayer JM The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Joint Bone Spine 2002, 69:123-132.
53. Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998, 25:1544-1552.
54. Danning CL, Illei GG, Hitchon C, et al. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000, 43:1244-1256.
55. Mizutani H, Ohmoto Y, Mizutani T, et al. Role of increased production of monocytes TNFα, IL-1b and II-6 in psoriasis: Relation to focal infection, disease activity and responses to treatments. J Dermatol Sci 1997, 14:145-153.
56. Partsch F, Steiner G, Leeb B, et al. Highly increased levels of tumor necrosis factorα and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997, 24:518-523.
57. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999, 38:241-251.
58. Ettehadi P, Greaves MW, Wallach D, et al. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994, 96:146-151.
59. Mussi A, Bonifati C, Carducci M, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997, 11:115-118.
60. Chodorowska G. Plasma concentrations of IFN-gamma and TNF-alpha in psoriatic patients before and after local treatment with dithranol ointment. J Eur Acad Dermatol Venereol 1998, 10:147-151.
61. Nickoloff BJ The immunologic and genetic basis of psoriasis. Arch Dermatol 1999, 135:1104-1110.
62. Krueger JG The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002, 46:1-23.
63. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986, 322:547-549.
64. Bertolini DR, Nedwin GE, Bringman TS, et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986, 319:516-518.
65. Shinmei M, Masuda K, Kikuchi T, et al. The role of cytokines in chondrocyte mediated cartilage degradation. J Rheumatol Suppl 1989, 18:32-34.
66. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985, 162:2163-2168.
67. Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003, 111:821-831.
68. Mease P. TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004, 63:755-758.
69. Silu A. Enbrel$$ (Etanercept) prescribing information 2003, Immunex Corporation, Thousand Oaks, Calif.
70. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000, 356:385-390.
71. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996, 39:2013-2020.
72. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727-735.
73. Fredriksson T, Pettersson U. Severe psoriasis-Oral therapy with a new retinoid. Dermatologica 1978, 157:238-244.
74. Fries JF, Spitz PW, Young DY The dimensions of health outcomes: The health assessment questionnaire, disability and pain scales. J Rheumatol 1982, 9:789-793.
75. Mease P, Goffe B, Metz J, et al. Enbrel (etanercept) in patients with psoriatic arthritis and psoriasis [abstract]. Ann Rheum Dis 2001, 60(1):146.
76. Mease P, Kivitz A, Burch F, et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264-2272.
77. Mease P, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006, 33:712-721.
78. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003, 349:2014-2022.
79. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol 2005, 152:1304-1312.
80. Johnsen A, Schiff M, Mease P, et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: A randomized double blind study. J Rheumatol 2006, 33:659-664.
81. Silu A. Remicade (infliximab) prescribing information 2003, Centocor, Malvern, PA.
82. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005, 52:1227-1236.
83. Mease P, Ganguly L, Wanke E, et al. How much improvement in functional status is considered important by patients with active psoriatic arthritis: Applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines [abstract]. Ann Rheum Dis 2004, 63(1):391.
84. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64:1150-1157.
85. Mease P, Kavanaugh A, Krueger G, et al. Infliximab improves psoriasis regardless of arthritis response in patients with active psoriatic arthritis: Results from IMPACT 2 Trial [abstract]. Arthritis Rheum 2004, 50(9):S616.
86. van der Heijde D, Gladman DD, Kavanaugh A, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis: 54 week results from IMPACT 2. Ann of Rheum Dis 2006, 65(11):85.
87. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003, 48:35-45.
88. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003, 30:2563-2571.
89. Keystone E, Haraoui B. Adalimumab therapy in rheumatoid arthritis. Rheum Dis Clin North Am 2004, 30:349-364.
90. van de Putte LB, Rau R, Breedveld FC, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: A 12 week, phase II study. Ann Rheum Dis 2003, 62:1168-1177.
91. Mease PJ Psoriatic arthritis/psoriasis. Targeted Therapies in Rheumatology 2003, 525-548. Martin Dunitz, London. J.S. Smolen, P.E. Lipsky (Eds.).
92. Ritchlin C, Anandarajaha A, Totterman S, et al. Preliminary data from a study of adalimumab in the treatment of psoriatic arthritis [abstract]. Ann Rheum Dis 2004, 63(1):403.
93. Mease P, Gladman D, Ritchlin C. Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: Results of ADEPT. Arthritis Rheum 2005, 58:3279-3289.
94. Genovese MC, Mease PJ, Thomson G, et al. Adalimumab efficacy in patients with psoriatic arthritis who failed prior DMARD therapy. Ann Rheum Dis 2005, 64(3):313.
95. Cohen M. RA therapy with biologics: Safety and long-term considerations. Rheumatology Educational Initiative (REDI): Making a Difference in Rheumatology 2004, 137-160. Veritas Institute for Medical Education, Hasbrouck Heights, NJ. M. Schiff (Ed.).
96. Devos SA, Van Den Bossche N, De Vos M, et al. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 2003, 206:388-390.
97. Davis JC, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum 2003, 48:3230-3236.
98. Mease P. TNFα inhibitors in psoriatic arthritis. Psoriasis and Psoriatic Arthritis: An Integrated Approach 2005, 223-234. Springer-Verlag, Heidelberg. K.B. Gordon, E.M. Ruderman (Eds.).
99. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: A large center experience. Am J Gastroenterol 2003, 98:1315-1324.
100. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001, 19:93-129.
101. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999, 130:478-486.
102. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
103. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
104. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343:1594-1602.
105. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
106. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 2002, 46:1443-1450.
107. Garcia I, Miyazaki Y, Araki K, et al. Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections. Eur J Immunol 1995, 25:2401-2407.
108. Ruderman E, Markenson J. Granulomatous infections and tumor necrosis factor antagonist therapies: Update through June 2002. Arthritis Rheum 2003, 48(9):S241.
109. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
110. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1 ra), for the treatment of rheumatic diseases. Ann Rheum Dis 2004, 3(2):ii2-ii12.
111. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001, 44:2862-2869.
112. Robinson WH, Genovese MC, Moreland LW Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?. Arthritis Rheum 2001, 44:1977-1983.
113. Beauparlant P, Papp K, Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999, 29:148-158.
114. Baecklund E, Ekbom A, Sparen P, et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: Nested case-control study. BMJ 1998, 317:180-181.
115. Shibata A, Zhao S, Makuch R, et al. Lymphoma risk in ankylosing spondylitis patients is greater than that observed in the general population [abstract]. Ann Rheum Dis 2004, 63(1):98.
116. Askling J, Klareskog L, Blomqvist P, et al. Risk for malignant lymphomas in ankylosing spondylitis. Ann Rheum Dis 2005, 64(3):64.
117. Gelfand JM, Berlin J, Van Voorhees A, et al. Lymphoma rates are low but increased in patients with psoriasis: Results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003, 139:1425-1429.
118. Schiff M, Burmester G, Pangan A, et al. Global safety in adalimumab (HUMIRA) rheumatoid arthritis clinical trials. Arthritis Rheum 2004, 50(9):S562.
119. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003, 138:807-811.
120. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: Rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004, 116:305-311.
121. Kazi S, Cole J, Busti A. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor-alpha antagonists. Arthritis Rheum 2004, 50(9):S374.
122. Ali Y, Shah S. Infliximab-induced systemic lupus erythematosus. Ann Intern Med 2002, 137:625-626.
123. Debandt M, Vittecoq O, Descamps V, et al. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 2003, 22:56-61.
124. Klapman JB, Ene-Stroescu D, Becker MA, et al. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 2003, 9:176-178.
125. Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002, 359:579-580.
126. Sari I, Akar S, Birkil M, et al. Anti-tumor necrosis factor-alpha-induced psoriasis. J Rheumatol 2006, 33:1411-1414.
127. Baert F, Noman M, Vermeire S, et al. Influence of immuno-genicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
128. Kraan MC, van Kuijk AW, Dinant HJ, et al. Alefacept treatment in psoriatic arthritis: Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002, 46:2776-2784.
129. Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002, 47:821-833.
130. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003, 139:719-727.
131. Mease PJ, Gladman DD, Keystone EC, Alefacept in Psoriatic Arthritis Study Group Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006, 54:1638-1645.
132. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003, 349:2004-2013.
133. Papp K, Mease P, Garovoy M, et al. Efalizumab in patients with psoriatic arthritis: Results of a phase II randomized double-blind placebo controlled study. International Psoriasis Symposium, Toronto, 2004.
134. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4lg. N Engl J Med 2003, 49:1907-1915.
135. Abrams JR, Lebwohl M, Guzzo C. CTLA4lg-mediated blockade of T cell co-stimulation in patients with psoriasis vulgaris. J Clin Invest 1999, 103:1243-1252.
136. Mclnnes IB, Gracie JA Interleukin-15: A new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004, 4:392-397.
137. Gibb A, Gogarty M, Veale D, et al. Efficacy of anakinara (Kineret) in psoriatic arthritis, a clinical and immunohisto-logical study. Ann Rheum Dis 2006, 65(3):216.
138. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the IL-6 receptor antagonist tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arth Rheum 2006, 54:2817-2829.
139. Krueger JG, Walters IB, Miyazawa M, et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000, 43:448-458.
140. Jung JH, Kavanaugh A. Other biologic therapy. Psoriasis and Psoriatic Arthritis: An Integrated Approach 2005, 223-234. Springer-Verlag, Heidelberg. K.B. Gordon, E.M. Ruderman (Eds.).
141. Mease PJ Recent advances in the management of psoriatic arthritis. Curr Opin Rheumatol 2004, 16:366-370.
142. Bongartz T, Coras B, Vogt T, et al. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: An open-label pilot study. Rheumatology (Oxford) 2005, 44:126-129.
143. Trepicchio WL, Ozawa M, Walters IB, et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999, 104:1527-1537.
144. Reich K, Garbe C, Blaschke V, et al. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol 2001, 116:319-329.
145. Mclnnes IB, Illei GG, Danning CL, et al. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol 2001, 167:4075-4082.
146. Utset TO, Auger JA, Peace D, et al. Modified anti-CD3 therapy in psoriatic arthritis: A phase I/II clinical trial. J Rheumatol 2002, 29:1907-1913.
147. Watson DJ, Rhodes T, Guess HA All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003, 30:1196-1202.
148. Navarro-Cano G, del Rincon I, Pogosian S, et al. Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity. Arthritis Rheum 2003, 48:2425-2433.
149. del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44:2737-2745.
150. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study. Arthritis Rheum 2005, 52:402-411.
151. Nielen MM, van Schaardenburg D, Reesink HW, et al. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum 2004, 50:2423-2427.
152. Bergholm R, Leirisalo-Repo M, Vehkavaara S, et al. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002, 22:1637-1641.
153. Yildiz M, Soy M, Kurum T, Ozbay G. Increased pulse wave velocity and shortened pulse wave propagation time in young patients with rheumatoid arthritis. Can J Cardiol 2004, 20:1097-1100.
154. Klocke R, Cockroft JR, Taylor GJ, et al. Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis. Ann Rheum Dis 2003, 62:414-418.
155. Ford DE, Erlinger TP Depression and C-reactive protein in US adults: Data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2004, 164:1010-1014.
156. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004, 15:447-450.
157. Hurlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002, 106:2184-2187.
158. Irace C, Marcuso G, Fiaschi E, et al. Effect of anti-TNF-alpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 2004, 177:113-118.
159. Han C, Robinson D, Hackett M, et al. Co-occurrences of selected cardiovascular disease and risk factors in patients with rheumatoid arthritis and psoriatic arthritis. Ann Rheum Dis 2005, 64(3):108.
160. Sattar N, Crompton P, Cherry L, et al. Effects of inflammatory suppression with onercept on vascular risk factors in psoriatic arthritis: Double-blind placebo-controlled study. Arthritis Rheum 2005, 52(9):S561.
161. Marzo-Ortega H, Mc Gonagle D, Haugeberg G, et al. Bone mineral density improvement in spondyloarthropathy after treatment with etanercept. Ann Reum Dis 2003, 62:1020-1021.
162. Romas E, Gillespie MT, Martin TJ Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002, 30:340-346.
163. Manolagas SC, Jilka RL Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995, 332:305-311.
164. Reddy S, Anandarajaha A, Reed G, et al. Comparative analysis of disease activity, radiographic features, and bone density in psoriatic and rheumatoid arthritis. Arthritis Rheum 2005, 52(9):S640.
165. Di Munno O, Delle Sedie A, Rossini M, et al. Disease-modifying antirheumatic drugs and bone mass in rheumatoid arthritis. Clin Exp Rheumatol 2005, 23:137-144.
166. Lange U, Teichmann J, Muller-Ladner U, et al. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: A prospective open-label pilot study. Rheumatology (Oxford) 2005, 44:1546-1548.
167. Allali F, Breban M, Porcher R, et al. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 2003, 62:347-349.
168. Briot K, Garnero P, Le Henanff A, et al. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor (alpha) treatment. Ann Rheum Dis 2005, 64:1137-1140.
169. Domis E, Reban M, Dougados M. Infliximab in spondylarthropathy influence on bone density. Clin Exp Rheumatol 2002, 20(28):S185-185.
170. Marzo-Ortega H, McGonagle D, Haugeberg G, et al. Bone mineral density improvement in spondyloarthropathy after treatment with etanercept. Ann Rheum Dis 2003, 62:1020-1021.
171. Anisman H, Hayley S, Turrin N, et al. Cytokines as a stressor: Implications for depressive illness. Int J Neuropsycho-pharmacol 2002, 5:357-373.
172. Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of depression: What can we learn from animal studies?. Neurosci Biobehav Rev 2005, 29:891-909.
173. Hayley S, Merali Z, Anisman H. Stress and cytokine-elicited neuroendocrine and neurotransmitter sensitization: Implications for depressive illness. Stress 2003, 6:19-32.
174. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.